X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs DR. REDDYS LAB - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA DR. REDDYS LAB ABBOTT INDIA/
DR. REDDYS LAB
 
P/E (TTM) x 38.0 41.8 90.8% View Chart
P/BV x 11.0 3.2 343.2% View Chart
Dividend Yield % 0.6 0.8 66.1%  

Financials

 ABBOTT INDIA   DR. REDDYS LAB
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-17
DR. REDDYS LAB
Mar-17
ABBOTT INDIA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs5,1903,397 152.8%   
Low Rs4,3512,560 170.0%   
Sales per share (Unadj.) Rs1,382.9856.5 161.5%  
Earnings per share (Unadj.) Rs130.278.0 167.0%  
Cash flow per share (Unadj.) Rs137.9139.9 98.6%  
Dividends per share (Unadj.) Rs40.0020.00 200.0%  
Dividend yield (eoy) %0.80.7 124.9%  
Book value per share (Unadj.) Rs652.7739.8 88.2%  
Shares outstanding (eoy) m21.25165.74 12.8%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x3.43.5 99.2%   
Avg P/E ratio x36.638.2 95.9%  
P/CF ratio (eoy) x34.621.3 162.5%  
Price / Book Value ratio x7.34.0 181.6%  
Dividend payout %30.725.7 119.8%   
Avg Mkt Cap Rs m101,373493,632 20.5%   
No. of employees `0003.122.7 13.6%   
Total wages/salary Rs m3,45331,068 11.1%   
Avg. sales/employee Rs Th9,531.96,259.0 152.3%   
Avg. wages/employee Rs Th1,119.91,369.8 81.8%   
Avg. net profit/employee Rs Th897.3569.7 157.5%   
INCOME DATA
Net Sales Rs m29,387141,961 20.7%  
Other income Rs m5761,715 33.6%   
Total revenues Rs m29,963143,676 20.9%   
Gross profit Rs m3,97324,722 16.1%  
Depreciation Rs m16410,266 1.6%   
Interest Rs m20634 3.2%   
Profit before tax Rs m4,36515,537 28.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m0349 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5982,965 53.9%   
Profit after tax Rs m2,76712,921 21.4%  
Gross profit margin %13.517.4 77.6%  
Effective tax rate %36.619.1 191.9%   
Net profit margin %9.49.1 103.4%  
BALANCE SHEET DATA
Current assets Rs m18,90696,837 19.5%   
Current liabilities Rs m6,29784,199 7.5%   
Net working cap to sales %42.98.9 482.0%  
Current ratio x3.01.2 261.1%  
Inventory Days Days6273 84.8%  
Debtors Days Days2298 22.2%  
Net fixed assets Rs m1,159102,552 1.1%   
Share capital Rs m213829 25.6%   
"Free" reserves Rs m13,657121,792 11.2%   
Net worth Rs m13,869122,621 11.3%   
Long term debt Rs m05,449 0.0%   
Total assets Rs m20,638218,165 9.5%  
Interest coverage x215.025.5 842.8%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.40.7 218.8%   
Return on assets %13.56.2 217.3%  
Return on equity %19.910.5 189.3%  
Return on capital %31.612.9 245.1%  
Exports to sales %054.6 0.0%   
Imports to sales %09.4 0.0%   
Exports (fob) Rs mNA77,520 0.0%   
Imports (cif) Rs mNA13,274 0.0%   
Fx inflow Rs m081,670 0.0%   
Fx outflow Rs m026,355 0.0%   
Net fx Rs m055,315 0.0%   
CASH FLOW
From Operations Rs m3,07221,444 14.3%  
From Investments Rs m-1,554-18,404 8.4%  
From Financial Activity Rs m-898-3,692 24.3%  
Net Cashflow Rs m621-1,144 -54.2%  

Share Holding

Indian Promoters % 0.0 25.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 5.4 146.3%  
FIIs % 0.1 35.3 0.3%  
ADR/GDR % 0.0 18.5 -  
Free float % 17.1 15.3 111.8%  
Shareholders   18,270 75,885 24.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   BIOCON LTD  CADILA HEALTHCARE  SUVEN LIFE  PANACEA BIOTECH  WOCKHARDT LTD.  

Compare ABBOTT INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens in Green; Pharma & Realty Stocks Gain(09:30 am)

Asian share markets are mixed today. The Nikkei 225 is flat while the Hang Seng is down 0.1%. The Shanghai Composite is trading down by 1.1%.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Jun 20, 2018 10:45 AM

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 5-YR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS